Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Envoy Medical Inc. (COCH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: COCH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.12
1 Year Target Price $7.12
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.22% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.63M USD | Price to earnings Ratio - | 1Y Target Price 7.12 |
Price to earnings Ratio - | 1Y Target Price 7.12 | ||
Volume (30-day avg) 4 | Beta 2.27 | 52 Weeks Range 1.21 - 3.99 | Updated Date 06/30/2025 |
52 Weeks Range 1.21 - 3.99 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -11102.17% |
Management Effectiveness
Return on Assets (TTM) -129.07% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 50706928 | Price to Sales(TTM) 153.91 |
Enterprise Value 50706928 | Price to Sales(TTM) 153.91 | ||
Enterprise Value to Revenue 239.18 | Enterprise Value to EBITDA -1.35 | Shares Outstanding 21326600 | Shares Floating 10658404 |
Shares Outstanding 21326600 | Shares Floating 10658404 | ||
Percent Insiders 50.15 | Percent Institutions 11.52 |
Analyst Ratings
Rating 2 | Target Price 7.12 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Envoy Medical Inc.
Company Overview
History and Background
Envoy Medical, Inc. (formerly known as Sound ID) was founded to create implantable medical technologies. They are known for their Esteem hearing implant.
Core Business Areas
- Hearing Restoration: Developing and commercializing fully implanted hearing solutions for sensorineural hearing loss.
Leadership and Structure
Details on the specific leadership team and organizational structure would require access to non-public information.
Top Products and Market Share
Key Offerings
- Esteem Fully Implanted Hearing Aid: Envoy Medical's primary product is the Esteem, a fully implanted hearing aid designed for individuals with moderate to severe sensorineural hearing loss. Market share data is difficult to ascertain due to limited sales and specialized nature. Competitors include Cochlear Limited (cochlear implants), Sonova (hearing aids and implants), and Medtronic (neurostimulation for hearing).
Market Dynamics
Industry Overview
The hearing aid and hearing implant market is characterized by a growing aging population, increasing awareness of hearing loss, and technological advancements in hearing solutions. Key trends include miniaturization, digital signal processing, and connectivity features.
Positioning
Envoy Medical is positioned as an innovator in fully implanted hearing solutions, differentiating itself from traditional hearing aids and cochlear implants by offering a completely invisible and maintenance-free hearing experience. However, they need to capture a much larger share of the market to be profitable.
Total Addressable Market (TAM)
The global hearing aids market is estimated to be $10 billion USD. The fully implanted hearing aid market is a smaller subset, but has the potential to grow as technology advances and awareness increases. Envoy Medical's position within the TAM is still nascent.
Upturn SWOT Analysis
Strengths
- Innovative and unique fully implanted hearing aid technology
- Potential for long-term patient satisfaction and adherence
- Completely invisible and maintenance-free operation
Weaknesses
- Limited market penetration and brand recognition
- High cost compared to traditional hearing aids
- Complex surgical procedure for implantation
- Limited number of trained surgeons to perform the procedure
- Dependence on a single product
Opportunities
- Expanding market for hearing solutions due to aging population
- Increasing awareness of hearing loss and its impact on quality of life
- Technological advancements in miniaturization and battery life
- Potential partnerships with ENT clinics and audiologists
Threats
- Competition from established hearing aid manufacturers
- Regulatory hurdles and reimbursement challenges
- Technological advancements in alternative hearing solutions
- Economic downturn affecting consumer spending on healthcare
Competitors and Market Share
Key Competitors
- COCH
- SONVF
- MDT
Competitive Landscape
Envoy Medical's advantage lies in its unique fully implanted technology. However, it faces significant disadvantages compared to established competitors with larger market share, brand recognition, and financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, with slow market penetration of the Esteem device.
Future Projections: Future growth depends on expanding market access, increasing sales of the Esteem device, and developing new hearing solutions.
Recent Initiatives: Recent initiatives would require access to company announcements and press releases.
Summary
Envoy Medical has a highly innovative product in the fully implanted hearing aid space, offering a unique advantage in terms of patient convenience and aesthetics. However, the company faces significant challenges related to market penetration, competition from established players, and the complexity of the surgical procedure. Success hinges on expanding market access, improving sales execution, and potentially developing new products. The company's long term viability depends on successfully scaling their implanted hearing aid and capturing more of the market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (Limited Access)
- Industry Reports
- News Articles
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The data provided is for informational purposes only and may not be entirely accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Envoy Medical Inc.
Exchange NASDAQ | Headquaters White Bear Lake, MN, United States | ||
IPO Launch date 2021-04-29 | CEO & Director Mr. Brent T. Lucas Esq. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 42 | Website https://www.envoymedical.com |
Full time employees 42 | Website https://www.envoymedical.com | ||
Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.